Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Elife. 2020 Sep 8;9:e58204. doi: 10.7554/eLife.58204.
Elife. 2020.
PMID: 32897190
Free PMC article.
Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells.
Sheffels E, Sealover NE, Theard PL, Kortum RL.
Sheffels E, et al. Among authors: theard pl.
Small GTPases. 2021 Jan;12(1):67-78. doi: 10.1080/21541248.2019.1611168. Epub 2019 May 7.
Small GTPases. 2021.
PMID: 31062644
Free PMC article.
Item in Clipboard
SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.
Theard PL, Linke AJ, Sealover NE, Daley BR, Yang J, Cox K, Kortum RL.
Theard PL, et al.
Mol Oncol. 2024 Mar;18(3):641-661. doi: 10.1002/1878-0261.13564. Epub 2024 Jan 18.
Mol Oncol. 2024.
PMID: 38073064
Free PMC article.
Item in Clipboard
SOS2 regulates the threshold of mutant EGFR-dependent oncogenesis.
Theard PL, Linke AJ, Sealover NE, Daley BR, Yang J, Cox K, Kortum RL.
Theard PL, et al.
bioRxiv [Preprint]. 2023 Jun 29:2023.01.20.524989. doi: 10.1101/2023.01.20.524989.
bioRxiv. 2023.
PMID: 37425733
Free PMC article.
Updated.
Preprint.
Item in Clipboard
In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies.
Sealover NE, Theard PL, Hughes JM, Linke AJ, Daley BR, Kortum RL.
Sealover NE, et al. Among authors: theard pl.
bioRxiv [Preprint]. 2023 Jun 28:2023.01.27.525958. doi: 10.1101/2023.01.27.525958.
bioRxiv. 2023.
PMID: 36747633
Free PMC article.
Updated.
Preprint.
Item in Clipboard
Cite
Cite